Pediatric Pharmacology

Pediatric pharmacology studies how infants and children handle and respond to medicines as their organs mature. The phrase 'children are not small adults' captures its central insight: drug absorption, distribution, metabolism, and elimination change continuously from the neonatal period through adolescence, so exposure and effect cannot be predicted by simply scaling adult data by body weight. Developmental pharmacology gives the conceptual framework for understanding these age-dependent differences.

Definition

The branch of clinical pharmacology concerned with the age-dependent maturation of drug absorption, distribution, metabolism, and elimination in infants and children, and with how these developmental changes alter drug exposure and response.

Scope

The entry covers the developmental physiology that shapes drug disposition across pediatric age bands — neonate, infant, child, and adolescent — including the maturation of drug-metabolizing enzymes and renal function, changes in body composition and protein binding, and the consequences for predicting drug exposure. It is a reference overview of developmental pharmacology and does not provide pediatric dosing or treatment instructions.

Core questions

• How do drug-metabolizing enzymes and renal function mature from birth through adolescence?
• Why does body composition (water, fat, and protein binding) at different ages change a drug's distribution volume?
• When can pediatric exposure be extrapolated from adults, and when are dedicated pediatric studies required?
• What role does therapeutic drug monitoring play where pediatric pharmacokinetics are highly variable?

Key concepts

• Developmental pharmacology (ontogeny of drug handling)
• Pediatric age classification (neonate, infant, child, adolescent)
• Maturation of cytochrome P450 and other enzymes
• Age-dependent renal clearance
• Body composition and distribution volume
• Plasma protein binding in neonates
• Therapeutic drug monitoring in neonates

Mechanisms

Drug disposition in children is governed by organ systems that mature on distinct timetables. Kearns and colleagues describe how gastric pH, gastric emptying, and intestinal transport affect oral absorption in early life; how a relatively larger proportion of body water and lower plasma protein binding raise the distribution volume of many drugs in neonates; how the major drug-metabolizing enzymes follow characteristic ontogenetic patterns, with some pathways immature at birth and others transiently exceeding adult activity in childhood; and how glomerular filtration and tubular function rise steeply over the first weeks to months of life. Because these processes change rapidly and vary between individuals, exposure for narrow-therapeutic-index drugs can be difficult to predict; Touw and colleagues illustrate how therapeutic drug monitoring is used to individualize aminoglycoside exposure in neonates. Rowland and Tozer supply the pharmacokinetic principles that connect these maturational changes to expected drug concentrations.

Clinical relevance

Developmental pharmacology underpins critical reading of pediatric drug information, much of which is extrapolated from adults because children are under-represented in trials. The topic describes why age-specific data and monitoring are needed and supports appraisal of the evidence; it is not a source of pediatric doses and does not substitute for pediatric clinical guidance.

Epidemiology

Historically a large fraction of medicines used in children were prescribed off-label or unlicensed for pediatric use, reflecting the scarcity of dedicated pediatric studies. Regulatory programmes requiring or incentivizing pediatric investigation have since expanded the evidence base, but gaps remain, particularly for neonates.

History

Modern pediatric pharmacology was shaped in part by mid-twentieth-century tragedies, including the 'gray baby syndrome' from chloramphenicol, which demonstrated that immature metabolism could turn an adult-appropriate dose into a toxic one. These lessons drove recognition that drug handling matures with age and, later, regulatory frameworks intended to ensure that medicines used in children are studied in children.

Debates

How far can adult and older-child data be extrapolated to younger children and neonates?

Extrapolation can reduce the burden of pediatric trials, but the rapid and uneven maturation of enzymes and renal function — most pronounced in neonates — limits how confidently adult or older-child exposure can be assumed to apply, and the appropriate balance remains debated.

Key figures

• Gregory Kearns
• J. Steven Leeder
• Daniel Touw

Seminal works

• kearns-2003
• touw-2009

Frequently asked questions

Why are children described as 'not small adults' in pharmacology?

Because the organs that absorb, metabolize, and eliminate drugs mature at different rates through childhood, age-specific differences in drug handling cannot be reproduced by simply scaling an adult dose to a child's body weight.

Why are many medicines used in children labelled off-label?

Children have historically been under-represented in clinical trials, so for many drugs there were no dedicated pediatric studies; regulatory programmes have since sought to increase pediatric investigation, though gaps persist.